Current Treatments for Alopecia Areata.
Current Treatments for Alopecia Areata.
复制标题
DOI：
10.1038/jidsymp.2015.41
复制
发表时间：
2015-11-01
期刊：
影响因子：
--
通讯作者：
Hordinsky, Maria K
中科院分区：
文献类型：
--
作者：
Hordinsky, Maria K
斑秃（AA）患者的治疗选择通常基于患者的年龄、疾病程度、可能的疾病持续时间、患者期望、在时间承诺方面的治疗成本、和财政资源、以及排除其他共病如贫血、低铁储存、甲状腺异常、低维生素D、或其他自身免疫性疾病。虽然目前没有治愈AA的方法，也没有普遍证明的诱导和维持缓解的治疗方法，但有许多治疗方法可以使受影响的儿童和成人受益。在为广泛的长期AA患者选择治疗方法之前，头皮活检可以提供有关炎症程度和卵泡分化的有用信息。最近对全身性Janus激酶（JAK）抑制剂和白细胞介素-2（IL-2）的临床和转化研究观察令临床和AA患者群体感到兴奋，并导致临床试验以及这些更昂贵和靶向全身治疗的标签外使用。
Selection of a therapy for a patient with alopecia areata (AA) is frequently based on the age of the patient, disease extent, perhaps disease duration, patient expectations, cost of therapy in terms of time commitment, and financial resources, as well as the results of screening laboratory studies that rule out the presence of other co-morbidities such as anemia, low iron stores, thyroid abnormalities, low vitamin D, or other autoimmune diseases. Although there is currently no cure for AA and no universally proven therapy that induces and sustains remission, many therapies are available which can be of benefit to both affected children and adults. Before selecting a treatment for patients with extensive long-standing AA, a scalp biopsy may provide useful information about the degree of inflammation and follicle differentiation. Recent clinical and translational research observations with the systemic Janus kinase (JAK) inhibitors and interleukin-2 (IL-2) have excited the clinical and AA patient communities and have led to clinical trials, as well as to the off-label use of these more expensive and targeted systemic therapies.